Riskpilot← Back to searchSign inGet full accessCONCEPTOMED AS
ASActiveOrg 998089433Hattvikveien 2, 8373 BallstadResearch and experimental development on natural sciences and engineering · NACE 7210Est. 20122 employeeswww.conceptomed.no
Revenue 2024
NOK 0
EBITDA margin
—
-40% vs 2023
Equity ratio
16.3%
Financial strength
Net profit 2024
NOK -6,7M
-45% vs 2023
| Revenue | NOK 0 | — |
| EBITDA | NOK -3,5M | -40% |
| Net profit | NOK -6,7M | -45% |
| Total assets | NOK 18,3M | -11% |
| Equity | NOK 3M | -69% |
| Employees | 2 | — |
Legal name
CONCEPTOMED AS
Org number
998089433
Legal form
Aksjeselskap
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
14. mars 2012
Share capital
NOK 401 087
Employees
2 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
To styremedlemmer i fellesskap. Styrets leder alene.
Company purpose
Innovasjon med utvikling, produksjon, eierskap/salg av idéer med tilhørende produkter og rettigheter, samt eierinteresser forøvrig.
Address
Hattvikveien 2, 8373 Ballstad
Website
www.conceptomed.no
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 499 | 257 | 797 | 1 145 | 419 | 781 | 892 | 103 | 200 | 14 122 | 0 | 447 | 0 |
| Staff expenses | −0 | −470 | −581 | −1 217 | −5 858 | −10 404 | −5 982 | −2 943 | −2 006 | −2 324 | −2 501 | −3 327 | −4 171 |
| EBITDA | −57 | −945 | −1 370 | −4 540 | −14 399 | −30 091 | −11 487 | −6 949 | −3 704 | 8 356 | −3 618 | −2 479 | −3 480 |
| Depreciation & amort. | −0 | −2 | −6 | −1 565 | −866 | −36 556 | −387 | −4 765 | −0 | −1 300 | −1 824 | −2 096 | −2 175 |
| EBIT | −57 | −947 | −1 376 | −6 105 | −15 265 | −66 647 | −11 875 | −11 714 | −3 704 | 7 056 | −5 441 | −4 575 | −5 655 |
| Net financials | 0 | 51 | 99 | 216 | 1 327 | 140 | −24 | 152 | 99 | −5 | −95 | −17 | −997 |
| Profit before tax | −57 | −897 | −1 277 | −5 889 | −13 938 | −66 507 | −11 899 | −11 562 | −3 605 | 7 051 | −5 536 | −4 593 | −6 652 |
| Tax | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| Net profit | −57 | −897 | −1 277 | −5 889 | −13 938 | −66 507 | −11 899 | −11 562 | −3 605 | 7 051 | −5 536 | −4 593 | −6 652 |
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 193 | 5 097 | 16 740 | 22 652 | 126 076 | 50 984 | 35 288 | 17 639 | 14 168 | 26 039 | 21 807 | 20 692 | 18 327 |
| Equity | 145 | 4 453 | 14 726 | 19 860 | 105 379 | 39 787 | 27 889 | 16 327 | 12 721 | 19 772 | 14 237 | 9 644 | 2 992 |
| Long-term debt | 0 | 0 | 0 | 0 | 7 500 | 7 500 | 6 250 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 49 | 644 | 2 013 | 2 792 | 13 197 | 3 696 | 1 150 | 1 312 | 1 408 | 6 141 | 7 358 | 10 715 | 14 888 |
| Total debt | 49 | 644 | 2 013 | 2 792 | 20 697 | 11 196 | 7 400 | 1 312 | 1 408 | 6 141 | 7 358 | 10 715 | 14 888 |
EBITDA margin
-347988800.0%
This company
15.8%
Market median
-2202460859% vs market
20122024
Equity ratio
16.3%
This company
38.2%
Market median
-57% vs market
20122024
Return on equity
-222.4%
This company
18.4%
Market median
-1309% vs market
20122024
Net profit margin
-665240400.0%
This company
8.1%
Market median
-8212844544% vs market
20122024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20122024
Debt / equity
5.13×
This company
0.62×
Market median
-727% vs market
20122024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Brønnøysundsregistrene · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Brønnøysundsregistrene · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Brønnøysundsregistrene · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via Brønnøysundsregistrene · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via Brønnøysundsregistrene · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via Brønnøysundsregistrene · Period 2012-01-01 – 2012-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
AL Chief Executive Officer | Chief Executive Officer | 2026 | — | — |
LJ Observer | Observer | 2024 | — | — |
CM Chief Executive Officer | Chief Executive Officer | 2012 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2020 | — | — | |
| Chairman | 2020 | — | — | |
| Board of Directors | 2023 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Brave Capital As | Company | 80.0% | 80.0% | 2024 |
Good Karma Invest As | Company | 57.5% | 57.5% | 2023 |
Xinvestor As | Company | 20.0% | 20.0% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Brave Capital As
CONCEPTOMED AS Board members of CONCEPTOMED AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Arild Lie | Chief Executive Officer | 0 companies |
| Lorenz Josef Pronnet | Observer | 0 companies |
| Christian Mide | Chief Executive Officer | 0 companies |
| Jostein Tveide | Board of Directors | 0 companies |
| Bård Baldishol | Chairman | 0 companies |
| Ludwig Georg Kuttner | Board of Directors | 0 companies |